Zhongke Shuaitian Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zhongke Shuaitian Pharmaceutical - overview
Established
2021
Location
Shenzhen, Guangdong, China
Primary Industry
Pharmaceuticals
About
Based in Shenzhen, China, and established in 2021, Zhongke Shuaitian Pharmaceutical is a pharmaceutical company that focuses on the R&D of new drugs for cancers. It was incubated from the Polymer Drug Research Centre of Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. In June 2023, Zhongke Shuaitian Pharmaceutical raised strategic investment from new investor Cowin Capital. Zhongke Shuaitian Pharmaceutical focuses on the R&D of small molecule precursor drugs and antibody-coupled drugs (ADC) in the field of anti-tumour.
Those drugs are non-toxic and inactive, and can improve therapeutic targeting. As well, those drugs can be used in the radiotherapy and chemotherapy combination treatments.
Current Investors
Nanshan SEI Investment, Cowin Capital, Shenzhen HTI
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.